The Experts below are selected from a list of 222 Experts worldwide ranked by ideXlab platform

Isidro B Salusky - One of the best experts on this subject based on the ideXlab platform.

  • correction bone canopies in pediatric Renal Osteodystrophy
    PLOS ONE, 2016
    Co-Authors: Renata C Pereira, Isidro B Salusky, Thomas Levin Andersen, Peter A Friedman, Navdeep Tumber, Katherine Wesselingperry
    Abstract:

    Fig 4 appears incorrectly in the published article. Please see the correct Fig 4 and its caption below. Fig 4 PTH levels as a function of the number of surfaces with canopy coverage in patients with Renal Osteodystrophy.

  • value of the new bone classification system in pediatric Renal Osteodystrophy
    Clinical Journal of The American Society of Nephrology, 2010
    Co-Authors: Sevcan A Bakkaloglu, Barbara Gales, Renata C Pereira, Katherine Wesselingperry, Hejing Wang, Robert Elashoff, Isidro B Salusky
    Abstract:

    Background and objectives: Although lesions of Renal Osteodystrophy have traditionally been defined by bone turnover, alterations in skeletal mineralization and volume are also prevalent and may contribute to significant morbidity in patients with chronic kidney disease (CKD). The study presented here was undertaken to compare the traditional spectrum of Renal Osteodystrophy defined by bone turnover to a new classification system that includes T (turnover), M (mineralization), and V (volume) and to determine the value of biochemical parameters as predictors of specific TMV lesions. Design, setting, participants, & measurements: Pediatric patients (n = 161) treated with peritoneal dialysis were enrolled into the study. Results: Increased bone turnover and abnormal mineralization were prevalent (57% and 48%, respectively); bone volume was normal or increased in all subjects. Predictive algorithms for different skeletal diagnoses were established by Classification and regression tree analysis. Serum parathyroid hormone (PTH) less than 400 pg/ml in combination with alkaline phosphatase values less than 400 IU/L provided the highest correct prediction rate for patients with both normal bone turnover and normal mineralization. Levels of PTH were higher and serum calcium levels were lower in patients with defective mineralization, irrespective of bone turnover. Conclusions: Although no single biochemical marker is able to provide a complete assessment of Renal Osteodystrophy, a combination of serum calcium, alkaline phosphatase, and PTH levels may lead to a more precise noninvasive assessment of turnover and mineralization abnormalities in this population.

  • special aspects of Renal Osteodystrophy in children
    Seminars in Nephrology, 2004
    Co-Authors: Isidro B Salusky, Beatriz D Kuizon, Harald Juppner
    Abstract:

    Renal Osteodystrophy represents a spectrum of skeletal lesions that range from high-turnover to low-turnover bone disease. Similar factors are involved in the pathogenesis of Renal Osteodystrophy in adult and pediatric patients with chronic kidney disease (CKD). However, growth retardation and the development of bone deformities are specific complications that occurred in pediatric patients with CKD. Metabolic acidosis, Renal Osteodystrophy, malnutrition, and disturbances in the insulin growth factor (IGF)/growth hormone (GH) are among the main factors involved and they are discussed briefly in this article. In addition to disturbances in bone remodeling, longitudinal bone growth occurs at the growth plate cartilage by endochondral ossification. Although young rats with experimental CKD have growth retardation, the characteristics of the growth plate are markedly different between animals with severe secondary hyperparathyroidism and those with calcium-induced adynamic Osteodystrophy. These disturbances may suggest potential molecular mechanisms by which endochondral bone formation may be altered in Renal failure, consequently leading to growth retardation.

  • cell biology of Renal Osteodystrophy
    Pediatric Nephrology, 2002
    Co-Authors: Beatriz D Kuizon, Isidro B Salusky
    Abstract:

    Renal Osteodystrophy, a well-recognized complication of chronic Renal failure, encompasses a spectrum of skeletal disorders ranging from high-turnover lesions of secondary hyperparathyroidism, the most common histologic lesion in pediatric patients with end-stage Renal disease, to low-turnover lesions of adynamic Renal Osteodystrophy, which has become a common skeletal lesion in adults with chronic Renal failure. Several advances have been made in the understanding of the pathogenesis of secondary hyperparathyroidism, particularly the critical roles of calcium, phosphorus, and vitamin D in promoting excess parathyroid hormone (PTH) synthesis and secretion, and parathyroid gland hyperplasia in Renal failure. These insights will guide the development of more effective strategies for the prevention and management of Renal bone disease.

  • adynamic Renal Osteodystrophy is there a problem
    Journal of The American Society of Nephrology, 2001
    Co-Authors: Isidro B Salusky, William G. Goodman
    Abstract:

    In recent years, adynamic Renal Osteodystrophy has become a common skeletal lesion in adult patients with chronic Renal failure ([1][1],[2][2],[3][3]). More than 40% of adults who are treated with hemodialysis and more than 50% of those who are treated with peritoneal dialysis have bone biopsy

Gino V Segre - One of the best experts on this subject based on the ideXlab platform.

  • Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD
    Kidney International, 1994
    Co-Authors: Isidro B Salusky, Gino V Segre, Jorge A Ramirez, William Oppenheim, Barbara Gales, William G. Goodman
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

  • biochemical markers of Renal Osteodystrophy in pediatric patients undergoing capd ccpd
    Kidney International, 1994
    Co-Authors: Gino V Segre, Isidro B Salusky, Jorge A Ramirez, William Oppenheim, Barbara Gales
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

  • Renal Osteodystrophy in diabetic patients
    Kidney International, 1993
    Co-Authors: Gavril Hercz, Celia M T Greenwood, Gino V Segre, Arif Manuel, Carl Saiphoo, Stanley S A Fenton, Donald J Sherrard
    Abstract:

    Renal Osteodystrophy in diabetic patients. To assess the effects of diabetes mellitus on Renal Osteodystrophy, we examined the database of 256 patients (45% on hemodialysis and 55% on peritoneal dialysis) who were prospectively studied in three Toronto dialysis centers between October of 1987 and 1989. All patients had serial documentation of their clinical, laboratory and risk parameters of bone disease, and completed a series of investigations that included the deferoxamine test, measurement of intact 1–84 PTH levels, and an iliac crest bone biopsy. Twenty-five percent of these patients were diabetic. When compared to non-diabetic patients, they were on dialysis for a shorter duration (2.4 ±0.3 vs. 4.7±0.3 years; P

Barbara Gales - One of the best experts on this subject based on the ideXlab platform.

  • value of the new bone classification system in pediatric Renal Osteodystrophy
    Clinical Journal of The American Society of Nephrology, 2010
    Co-Authors: Sevcan A Bakkaloglu, Barbara Gales, Renata C Pereira, Katherine Wesselingperry, Hejing Wang, Robert Elashoff, Isidro B Salusky
    Abstract:

    Background and objectives: Although lesions of Renal Osteodystrophy have traditionally been defined by bone turnover, alterations in skeletal mineralization and volume are also prevalent and may contribute to significant morbidity in patients with chronic kidney disease (CKD). The study presented here was undertaken to compare the traditional spectrum of Renal Osteodystrophy defined by bone turnover to a new classification system that includes T (turnover), M (mineralization), and V (volume) and to determine the value of biochemical parameters as predictors of specific TMV lesions. Design, setting, participants, & measurements: Pediatric patients (n = 161) treated with peritoneal dialysis were enrolled into the study. Results: Increased bone turnover and abnormal mineralization were prevalent (57% and 48%, respectively); bone volume was normal or increased in all subjects. Predictive algorithms for different skeletal diagnoses were established by Classification and regression tree analysis. Serum parathyroid hormone (PTH) less than 400 pg/ml in combination with alkaline phosphatase values less than 400 IU/L provided the highest correct prediction rate for patients with both normal bone turnover and normal mineralization. Levels of PTH were higher and serum calcium levels were lower in patients with defective mineralization, irrespective of bone turnover. Conclusions: Although no single biochemical marker is able to provide a complete assessment of Renal Osteodystrophy, a combination of serum calcium, alkaline phosphatase, and PTH levels may lead to a more precise noninvasive assessment of turnover and mineralization abnormalities in this population.

  • calcium regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy
    Kidney International, 1995
    Co-Authors: Jorge A Ramirez, Barbara Gales, William G. Goodman, Cheryl P Sanchez, Thomas R Belin
    Abstract:

    Calcium-regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy. Hypercalcemia and low serum parathyroid hormone (PTH) levels are features of the adynamic lesion (AD) of Renal Osteodystrophy, but there is little information about parathyroid gland function in this disorder. Therefore, the four parameter model was used to evaluate calcium-regulated PTH release in patients with either adynamic bone or secondary hyperparathyroidism (OF) as documented by bone biopsy and in normal volunteers (NL). Patients had undergone CCPD for 20 ± 4.2 months, and all received calcium carbonate as the sole phosphate-binding agent. During two hours infusions of sodium citrate, the rate of decline in serum ionized calcium levels did not differ among groups; serum PTH levels rose from 136 ± 38 to 342 ± 140 pg/ml in AD and from 691 ± 99 to 869 ±121 pg/ml in OF. Maximum PTH levels were 322 ± 42% of baseline values in AD but only 146 ± 9.7% of baseline in OF (P

  • Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD
    Kidney International, 1994
    Co-Authors: Isidro B Salusky, Gino V Segre, Jorge A Ramirez, William Oppenheim, Barbara Gales, William G. Goodman
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

  • biochemical markers of Renal Osteodystrophy in pediatric patients undergoing capd ccpd
    Kidney International, 1994
    Co-Authors: Gino V Segre, Isidro B Salusky, Jorge A Ramirez, William Oppenheim, Barbara Gales
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

Jorge A Ramirez - One of the best experts on this subject based on the ideXlab platform.

  • calcium regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy
    Kidney International, 1995
    Co-Authors: Jorge A Ramirez, Barbara Gales, William G. Goodman, Cheryl P Sanchez, Thomas R Belin
    Abstract:

    Calcium-regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy. Hypercalcemia and low serum parathyroid hormone (PTH) levels are features of the adynamic lesion (AD) of Renal Osteodystrophy, but there is little information about parathyroid gland function in this disorder. Therefore, the four parameter model was used to evaluate calcium-regulated PTH release in patients with either adynamic bone or secondary hyperparathyroidism (OF) as documented by bone biopsy and in normal volunteers (NL). Patients had undergone CCPD for 20 ± 4.2 months, and all received calcium carbonate as the sole phosphate-binding agent. During two hours infusions of sodium citrate, the rate of decline in serum ionized calcium levels did not differ among groups; serum PTH levels rose from 136 ± 38 to 342 ± 140 pg/ml in AD and from 691 ± 99 to 869 ±121 pg/ml in OF. Maximum PTH levels were 322 ± 42% of baseline values in AD but only 146 ± 9.7% of baseline in OF (P

  • Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD
    Kidney International, 1994
    Co-Authors: Isidro B Salusky, Gino V Segre, Jorge A Ramirez, William Oppenheim, Barbara Gales, William G. Goodman
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

  • biochemical markers of Renal Osteodystrophy in pediatric patients undergoing capd ccpd
    Kidney International, 1994
    Co-Authors: Gino V Segre, Isidro B Salusky, Jorge A Ramirez, William Oppenheim, Barbara Gales
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.

William G. Goodman - One of the best experts on this subject based on the ideXlab platform.

  • adynamic Renal Osteodystrophy is there a problem
    Journal of The American Society of Nephrology, 2001
    Co-Authors: Isidro B Salusky, William G. Goodman
    Abstract:

    In recent years, adynamic Renal Osteodystrophy has become a common skeletal lesion in adult patients with chronic Renal failure ([1][1],[2][2],[3][3]). More than 40% of adults who are treated with hemodialysis and more than 50% of those who are treated with peritoneal dialysis have bone biopsy

  • calcium regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy
    Kidney International, 1995
    Co-Authors: Jorge A Ramirez, Barbara Gales, William G. Goodman, Cheryl P Sanchez, Thomas R Belin
    Abstract:

    Calcium-regulated parathyroid hormone secretion in adynamic Renal Osteodystrophy. Hypercalcemia and low serum parathyroid hormone (PTH) levels are features of the adynamic lesion (AD) of Renal Osteodystrophy, but there is little information about parathyroid gland function in this disorder. Therefore, the four parameter model was used to evaluate calcium-regulated PTH release in patients with either adynamic bone or secondary hyperparathyroidism (OF) as documented by bone biopsy and in normal volunteers (NL). Patients had undergone CCPD for 20 ± 4.2 months, and all received calcium carbonate as the sole phosphate-binding agent. During two hours infusions of sodium citrate, the rate of decline in serum ionized calcium levels did not differ among groups; serum PTH levels rose from 136 ± 38 to 342 ± 140 pg/ml in AD and from 691 ± 99 to 869 ±121 pg/ml in OF. Maximum PTH levels were 322 ± 42% of baseline values in AD but only 146 ± 9.7% of baseline in OF (P

  • Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD
    Kidney International, 1994
    Co-Authors: Isidro B Salusky, Gino V Segre, Jorge A Ramirez, William Oppenheim, Barbara Gales, William G. Goodman
    Abstract:

    Biochemical markers of Renal Osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of Renal Osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of Renal Osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of Renal Osteodystrophy from those with secondary hyperparathyroidism.